I'm LongbridgeAI, I can summarize articles.Hong Kong's overlooked small-cap stocks are rewriting their narratives through strategic pivots and innovation breakthroughs. Junshi Bio (1877.HK) demonstrated a 34% reduction in death risk for resectable lung cancer patients in its NEOTORCH Phase III trial, with results published in Annals of Oncology and under NMPA review for perioperative indication expansion. Concurrently, ImmuStar Biopharma (1541.HK) reported over 88% ORR for IMM0306 in lymphoma treatment, triggering a 6% stock surge.
In wealth management, Noah Holdings (6686.HK) achieved 30% year-on-year net profit growth in Q2 with international business rising 16% sequentially, as its Singapore AI wealth division turned monthly profitable. Zhongwei New Materials (2579.HK) advanced its USD 895 million Indonesia nickel restructuring to strengthen resource control, maintaining global leadership in ternary precursor cathode materials.
Traditional sector transformations are equally notable: Dongguan Rural Commercial Bank (9889.HK) posted 10% revenue and profit growth in H1 but faces asset quality pressure with NPL ratio at 1.93%. Synergy Communications (1613.HK) relocated smart building production to Australia despite a 30% wider FY2026 loss. Yichen Group (8365.HK) announced multiple acquisitions within one month including Hengrui Group while expanding into Web3 and AI healthcare. Viva Biotech (1873.HK) partnered with Xidian Pharma on AI-driven reverse target discovery with 21% H1 revenue growth, while Jiangxi Bio (6915.HK) made its third IPO attempt with R&D expenditure up 18.6% for its tetanus antitoxin business.
